Journal of Clinical Oncology, Vol 23, No 25 (September 1), 2005: pp. 6220-6232
© 2005 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.11.593
Adjuvant Therapy in Gastric Cancer
Lionel Lim,
Michael Michael,
G. Bruce Mann,
Trevor Leong
From the Peter MacCallum Cancer Centre, St Andrew's Place, East Melbourne, Victoria, Australia
Address reprint requests to Michael Michael, MD, Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia; e-mail: michael.michael{at}petermac.org
Gastric cancer has a poor prognosis. The majority of patients will relapse after definitive surgery, and 5-year survival after surgery remains poor. The role of adjuvant therapy in gastric cancer has been controversial given the lack of significant survival benefit in many randomized studies so far. The results of a large North American study (Gastrointestinal Cancer Intergroup Trial INT 0116) reported that postoperative chemoradiotherapy conferred a survival advantage compared with surgery alone, which has led to the regimen being adopted as a new standard of care. However, controversies still remain regarding surgical technique, the place of more effective and less toxic chemotherapy regimens, and the use of more modern radiation planning techniques to improve treatment delivery and outcome in the adjuvant and neoadjuvant setting. This article reviews the current status of the adjuvant treatment for gastric cancer including discussion on the research directions aimed at optimizing treatment efficacy. Issues such as the identification of patients who are more likely to benefit from adjuvant therapy are also addressed. Further clinical trials are needed to move towards better consensus and standardization of care.
Authors' disclosures of potential conflicts of interest are found at the end of this article.
This article has been cited by other articles:

|
 |

|
 |
 
R. Persiani, S. Rausei, C. Pozzo, A. Biondi, C. Barone, F. C. M. Cananzi, G. Schinzari, and D. D'Ugo
7-Year Survival Results of Perioperative Chemotherapy with Epidoxorubicin, Etoposide, and Cisplatin (EEP) in Locally Advanced Resectable Gastric Cancer: Up-to-date Analysis of a Phase-II Study
Ann. Surg. Oncol.,
August 1, 2008;
15(8):
2146 - 2152.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Di Costanzo, S. Gasperoni, L. Manzione, G. Bisagni, R. Labianca, S. Bravi, E. Cortesi, P. Carlini, R. Bracci, S. Tomao, et al.
Adjuvant Chemotherapy in Completely Resected Gastric Cancer: A Randomized Phase III Trial Conducted by GOIRC
J Natl Cancer Inst,
March 19, 2008;
100(6):
388 - 398.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Cascinu, R. Labianca, C. Barone, A. Santoro, C. Carnaghi, A. Cassano, G. D. Beretta, V. Catalano, O. Bertetto, S. Barni, et al.
Adjuvant Treatment of High-Risk, Radically Resected Gastric Cancer Patients With 5-Fluorouracil, Leucovorin, Cisplatin, and Epidoxorubicin in a Randomized Controlled Trial
J Natl Cancer Inst,
April 18, 2007;
99(8):
601 - 607.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. W. Gee and D. W. Rattner
Management of Gastroesophageal Tumors
Oncologist,
February 1, 2007;
12(2):
175 - 185.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|